These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23065656)

  • 41. Protein kinase Cbeta is an effective target for chemoprevention of colon cancer.
    Fields AP; Calcagno SR; Krishna M; Rak S; Leitges M; Murray NR
    Cancer Res; 2009 Feb; 69(4):1643-50. PubMed ID: 19221092
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.
    Kilburn LB; Kocak M; Decker RL; Wetmore C; Chintagumpala M; Su J; Goldman S; Banerjee A; Gilbertson R; Fouladi M; Kun L; Boyett JM; Blaney SM
    Neuro Oncol; 2015 Feb; 17(2):303-11. PubMed ID: 25431212
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enzastaurin.
    Ma S; Rosen ST
    Curr Opin Oncol; 2007 Nov; 19(6):590-5. PubMed ID: 17906457
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma.
    Schwartzberg L; Hermann R; Flinn I; Flora D; Hsi ED; Hamid O; Shi P; Lin BK; Myrand SP; Nguyen TS; Dreyling M
    Br J Haematol; 2014 Jul; 166(1):91-7. PubMed ID: 24673609
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biological activity of celecoxib in the bronchial epithelium of current and former smokers.
    Kim ES; Hong WK; Lee JJ; Mao L; Morice RC; Liu DD; Jimenez CA; Eapen GA; Lotan R; Tang X; Newman RA; Wistuba II; Kurie JM
    Cancer Prev Res (Phila); 2010 Feb; 3(2):148-59. PubMed ID: 20103722
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
    Moreau AS; Jia X; Ngo HT; Leleu X; O'Sullivan G; Alsayed Y; Leontovich A; Podar K; Kutok J; Daley J; Lazo-Kallanian S; Hatjiharissi E; Raab MS; Xu L; Treon SP; Hideshima T; Anderson KC; Ghobrial IM
    Blood; 2007 Jun; 109(11):4964-72. PubMed ID: 17284528
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression.
    Verdelli D; Nobili L; Todoerti K; Intini D; Cosenza M; Civallero M; Bertacchini J; Deliliers GL; Sacchi S; Lombardi L; Neri A
    Hematol Oncol; 2009 Mar; 27(1):23-30. PubMed ID: 18759374
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemonaive patients with advanced non-small cell lung cancer.
    Vansteenkiste J; Ramlau R; von Pawel J; San Antonio B; Eschbach C; Szczesna A; Kennedy L; Visseren-Grul C; Chouaki N; Reck M
    Oncology; 2012; 82(1):25-9. PubMed ID: 22269428
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term impact of smoking on lung epithelial proliferation in current and former smokers.
    Lee JJ; Liu D; Lee JS; Kurie JM; Khuri FR; Ibarguen H; Morice RC; Walsh G; Ro JY; Broxson A; Hong WK; Hittelman WN
    J Natl Cancer Inst; 2001 Jul; 93(14):1081-8. PubMed ID: 11459869
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial.
    Omenn GS; Goodman GE; Thornquist MD; Balmes J; Cullen MR; Glass A; Keogh JP; Meyskens FL; Valanis B; Williams JH; Barnhart S; Cherniack MG; Brodkin CA; Hammar S
    J Natl Cancer Inst; 1996 Nov; 88(21):1550-9. PubMed ID: 8901853
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting protein kinase C by Enzastaurin restrains proliferation and secretion in human pancreatic endocrine tumors.
    Molè D; Gagliano T; Gentilin E; Tagliati F; Pasquali C; Ambrosio MR; Pansini G; Degli Uberti EC; Zatelli MC
    Endocr Relat Cancer; 2011 Aug; 18(4):439-50. PubMed ID: 21606156
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma.
    Jourdan E; Leblond V; Maisonneuve H; Benhadji KA; Hossain AM; Nguyen TS; Wooldridge JE; Moreau P
    Leuk Lymphoma; 2014 Sep; 55(9):2013-7. PubMed ID: 24180331
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies.
    Ysebaert L; Morschhauser F
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1167-74. PubMed ID: 21639821
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention.
    Khuri FR
    Clin Lung Cancer; 2003 Sep; 5 Suppl 1():S36-40. PubMed ID: 14641993
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlations of mRNA expression and in vitro chemosensitivity to enzastaurin in freshly explanted human tumor cells.
    Hanauske AR; Eismann U; Oberschmidt O; Pospisil H; Hanauske-Abel HM; Blatter J; Ma D; Chen V; Lahn M
    Invest New Drugs; 2008 Jun; 26(3):215-22. PubMed ID: 18000644
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The finding of premalignant lesions is not associated with smoking cessation in chemoprevention study volunteers.
    Schook RM; Postmus BB; van den Berg RM; Sutedja TG; Man de FS; Smit EF; Postmus PE
    J Thorac Oncol; 2010 Aug; 5(8):1240-5. PubMed ID: 20581710
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The PKC-β selective inhibitor, Enzastaurin, impairs memory in middle-aged rats.
    Willeman MN; Mennenga SE; Siniard AL; Corneveaux JJ; De Both M; Hewitt LT; Tsang CWS; Caselli J; Braden BB; Bimonte-Nelson HA; Huentelman MJ
    PLoS One; 2018; 13(6):e0198256. PubMed ID: 29870545
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.
    Casey EM; Harb W; Bradford D; Bufill J; Nattam S; Patel J; Fisher W; Latz JE; Li X; Wu J; Hanna N
    J Thorac Oncol; 2010 Nov; 5(11):1815-20. PubMed ID: 20881647
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Surrogate end-point biomarker analysis in a retinol chemoprevention trial in current and former smokers with bronchial dysplasia.
    Lam S; Xu X; Parker-Klein H; Le Riche JC; Macaulay C; Guillaud M; Coldman A; Gazdar A; Lotan R
    Int J Oncol; 2003 Dec; 23(6):1607-13. PubMed ID: 14612933
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia.
    Ghobrial IM; Moreau P; Harris B; Poon T; Jourdan E; Maisonneuve H; Benhadji KA; Hossain AM; Nguyen TS; Wooldridge JE; Leblond V
    Clin Cancer Res; 2012 Sep; 18(18):5043-50. PubMed ID: 22879385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.